Solventum (SOLV) Set to Announce Earnings on Thursday

Solventum (NYSE:SOLV) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $1.34 per share and revenue of $1.93 billion for the quarter. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the firm posted $1.69 EPS. The business’s quarterly revenue was up 2.2% on a year-over-year basis. On average, analysts expect Solventum to post $7.20 EPS for the current fiscal year and $7.24 EPS for the next fiscal year.

Solventum Trading Down 0.7%

Shares of SOLV stock traded down $0.62 on Tuesday, reaching $84.13. 32,533 shares of the company’s stock were exchanged, compared to its average volume of 1,291,924. The stock has a market capitalization of $14.32 billion, a PE ratio of 10.28, a P/E/G ratio of 1.20 and a beta of 0.63. Solventum has a 52 week low of $62.38 and a 52 week high of $94.16. The company’s fifty day simple moving average is $88.02 and its 200 day simple moving average is $78.54. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. BMO Capital Markets initiated coverage on Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price objective on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Wedbush upped their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Piper Sandler lifted their target price on Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Solventum has an average rating of “Moderate Buy” and a consensus target price of $87.55.

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.